Evidence map›Paper›PMID 42068011›Full record

SynthesisDrug delivery2026

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Amirhossein Masroor, Nienke Streefkerk, Martine Van Grotel, James I Geller, Marc Ansari, Eric Bouffet, Archie Bleyer, Brice Fresneau, Michael Sullivan, Kristin Knight and 10 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Amirhossein MasroorPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Nienke StreefkerkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Martine Van GrotelPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
James I GellerDivision of Hematology/Oncology, Department of Pediatrics, Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, CA, United States of America.
Marc AnsariDepartment of Pediatrics, Gynecology and Obstetrics, Cansearch Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Eric BouffetDivision of Pediatric Neuro-Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Archie BleyerDepartment of Radiation Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, United States of America.
Brice FresneauDepartment of Children and Adolescents Oncology, Gustave Roussy, University Paris Saclay and Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Michael SullivanChildren's Cancer Centre and Department of Pediatric Oncology, Royal Children's Hospital, Melbourne, Victoria, Australia.
Kristin KnightDepartment of Pediatric Audiology, Oregon Health and Science University, Portland, OR, United States of America.
Per KognerDepartment of Women's and Children's Health, Pediatric Oncology, Karolinska University Hospital and Childhood Cancer Research Unit, Karolinska Institutet, Stockholm, Sweden.
Rudolf MaibachETOP IBCSG Partners Foundation, Bern, Switzerland.
Allison F O'neillDana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, United States of America.
Vassilios PapadakisDepartment of Pediatric Hematology-Oncology (TAO), Agia Sofia Children's Hospital, Athens, Greece.
Kaukab M RajputDepartment of Pediatric Audiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
Penelope R BrockDepartment of Pediatric Audiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
Gareth J VealNewcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Alexander E HoetinkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Alwin D R HuitemaPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Marry M Van Den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin-induced hearing loss (CIHL) in pediatric cancer patients is an irreversible and highly prevalent adverse effect with a devastating impact on quality of life. Sodium thiosulfate (STS) has recently been approved for systemic administration as an otoprotective agent in children. However, implementation of systemic STS has its challenges, and there is currently limited evidence to support local STS for children. This review investigates the potential value of locally administered otoprotective agents other than STS with a focus on future pediatric implementation. We conducted a systematic review on the efficacy and safety of locally applied non-STS otoprotective agents in

Indexed as

Antineoplastic AgentsCisplatinHearing LossProtective AgentsThiosulfatesAcetylcysteineAnimalsChildDexamethasoneHumansAcetylcysteineAntineoplastic AgentsCisplatinDexamethasoneProtective Agentssodium thiosulfateThiosulfatesChildhood cancercisplatinhearing losslocal intratympanic otoprotectionototoxicity

Identifiers

PMID42068011
PMCPMC13137753

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.